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AbstrACt
Introduction Permanent artificial pacemaker implantation 
is a safe and effective treatment for bradycardia and is 
associated with extended longevity and improved quality 
of life. However, the most common long-term complication 
of standard pacemaker therapy is pacemaker-associated 
heart failure. Pacemaker follow-up is potentially an 
opportunity to screen for heart failure to assess and 
optimise patient devices and medical therapy.
Methods and analysis The study is a multicentre, 
phase-3 randomised trial. The 1200 participants will be 
people who have a permanent pacemaker for bradycardia 
for at least 12 months, randomly assigned to undergo 
a transthoracic echocardiogram with their pacemaker 
check, thereby tailoring their management directed by 
left ventricular function or the pacemaker check alone, 
continuing with routine follow-up. The primary outcome 
measure is time to all-cause mortality or heart failure 
hospitalisation. Secondary outcomes include external 
validation of our risk stratification model to predict onset of 
heart failure and quality of life assessment.
Ethics and Dissemination The trial design and protocol 
have received national ethical approval (12/YH/0487). 
The results of this randomised trial will be published in 
international peer-reviewed journals, communicated to 
healthcare professionals and patient involvement groups 
and highlighted using social media campaigns.
trial registration number NCT01819662.
IntroDuCtIon
Permanent artificial pacemaker implan-
tation is a safe and effective treatment for 
bradycardia1 and is associated with extended 
longevity2 and improved quality of life.3 An 
estimated 350 000 people in the UK have a 
pacemaker, with over 40 000 new implants 
per year.
However, long-term right ventricular (RV) 
pacing has been linked to adverse left ventric-
ular (LV) remodelling,4 5 such that the most 
common long-term complication of standard 
pacemaker therapy is pacemaker-associated 
chronic heart failure (CHF) due to left 
ventricular systolic dysfunction (LVSD).6–8 
While up to 2%–3% of the general popula-
tion have CHF, the condition is much more 
common in pacemaker patients with a prev-
alence up to 50%7 9 and 12% of people 
admitted with acute decompensated heart 
failure (HF) (4% with a de novo admission 
for  HF) have a pacemaker.10
It is clear that RV pacing alone can lead 
to LVSD; however, the risk is especially 
high in people requiring a high proportion 
of ventricular pacing, those with diabetes 
mellitus, previous myocardial infarction 
and raised creatinine.11 Data examining the 
relationship between pacemaker use and 
cardiac dysfunction predominantly origi-
nate from retrospective cross-sectional anal-
ysis or secondary analyses.12–15 We provided 
the first evidence that reducing RV pacing 
through careful reprogramming is associated 
with an improvement in LV function without 
affecting quality of life or functional capacity,9 
confirming somewhat the suggestion that RV 
pacing is contributory to LV dysfunction in 
pacemaker patients and not just a bystander 
in a multimorbid patient population.
Although there is increasing recogni-
tion of the axis of RV pacing and LVSD, it 
strengths and limitations of this study
 ► OPTimising PACEmaker therapy is a trial inde-
pendently funded by the National Institute for Health 
Research.
 ► Stratification of the participant randomisation is not 
adopted in this trial due to the large sample size.
 ► Participant and practitioner blinding are not 
plausible. 
 ► The control arm consists of current standard of care 
ensuring trial results are reflective and generalizable.
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remains the case that HF is frequently overlooked in the 
pacemaker population with symptoms often ascribed 
to pacemaker syndrome, chronotropic incompetence 
or comorbidities.6 HF and undiagnosed LV dysfunction 
have a major effect on mortality and morbidity among 
pacemaker patients.16–18 Since HF management accounts 
for approximately 2% of the healthcare budget in many 
developed countries, more than 60% of which relates to 
hospitalisation costs,19 optimal management of people 
with HF whether or not they have a pacemaker is a key 
strategy for controlling healthcare costs while increasing 
quality of life.20
There are, however, no data on the potential benefits of 
screening people with pacemakers for HF, and while there 
are now a series of algorithms to limit RV pacing,21–23 no 
clear strategy for the use of these is outlined in current 
guidelines. This situation is compounded by a lack of 
published evidence around the benefits of medical 
management of pacemaker-related HF since people with 
pacemakers were excluded from most of the large HF 
studies.
Prospective randomised studies of pacemaker follow-up 
programmes to risk stratify patients and optimise manage-
ment have not yet been of adequate size and duration 
to assess the clinical effectiveness of such an approach 
in a real-world general healthcare setting. Pacemaker 
follow-up is a rarely realised opportunity to screen for 
HF and assess and optimise patient devices and medical 
therapy.24
The OPTimising PACEmaker therapy (OPT-PACE) 
trial has been designed to address these issues and quan-
tify time to all-cause mortality or HF hospitalisation, as 
well as validate a HF risk stratification model based on 
simple variables available in pacemaker clinic. Secondary 
aims are to establish whether N-terminal prohormone of 
brain natriuretic peptide (NT-proBNP) improves this risk 
stratification model. Subsequently, we aim to provide data 
on the effects of establishing the presence of LVSD  on 
medical therapy, device programming and patient quality 
of life.
Pilot data
Risk model
The design of the OPT-PACE trial is informed by an 
observational cohort11 including 491 patients listed for 
a pacemaker generator replacement in a single tertiary 
centre (Leeds Teaching Hospitals NHS Trust) invited for 
pacing therapy information, diagnostic pacing data and 
an echocardiogram.
Of this cohort, 40% had a left ventricular  ejection frac-
tion (LVEF) of <50%, which was much higher (59%) in 
those with >80% RV pacing (p<0.001), demonstrating 
that patients with RV pacemakers have a high prevalence 
of LVSD. After a mean follow-up time of 668 days, 56 
patients (12%) had died or been hospitalised for HF.
Multivariable analyses identified a number of simple 
clinical variables; high percentage RV pacing, high serum 
creatinine and previous myocardial infarction as potential 
independent predictors of LVSD to identify patients who 
may benefit from a more comprehensive review.11 This 
risk model requires external validation planned within 
the OPT-PACE trial.
Intervention development
The design of the pacemaker optimisation intervention 
used in the OPT-PACE trial is based on data from an obser-
vational cohort of 66 patients, referred for pacemaker 
generator replacement, recruited consecutively from 
a single tertiary centre (Leeds Teaching Hospitals NHS 
Trust).9 All patients recruited had been referred for pace-
maker generator replacement. Exclusion criteria were 
inability to consent, underlying complete heart block, a 
life expectancy of <1 year in the opinion of the clinician 
(eg, terminal malignancy), the presence of a device-re-
lated complication or those with known LVEF <50%.
In patients recruited with avoidable RV pacing, a 
prespecified protocol was followed to reduce this as 
outlined in figure 1, including a reduction in the diurnal 
base rate (BR) to 50 beats/min with nocturnal rate or 
hysteresis to 40 beats/min along with the deactivation 
of rate-adaptive pacing. In addition, where sinus rhythm 
and heart block had been documented, the atrioventric-
ular delays were extended or a device with RV avoidance 
algorithms was implanted. The patients were reassessed 6 
months post randomisation. The primary endpoint was 
LVEF at follow-up calculated as an average over three 
non-paced, normally conducted beats using modified 
Simpson’s method as per American Society of Echocar-
diogrpahy guidelines.25 The protocol was tolerated in 
all but two subjects in whom rate-responsive pacing was 
reactivated. Nevertheless, application of the protocol 
reduced absolute RV pacing percentage by a mean of 
49% (95% CI 41% to 57%; p<0.0001) from baseline and 
resulted in a mean absolute improvement in LVEF of 6% 
(95% CI 2% to 8%; p<0.0001). This occurred without 
reduction in exercise capacity, NT-proBNP or quality of 
life. An association was seen between the reduction in RV 
pacing and magnitude of change in LVEF (p=0.04). The 
intervention was considered safe to use without adapta-
tion in OPT-PACE.
MEthoDs AnD AnAlysIs
OPT-PACE is a multicentre, randomised, non-blinded 
parallel trial funded by the National Institute for Health 
Research (NIHR) in the UK (NIHR-CS-2012-032) and 
registered with the Clinical Trials registry. The trial design 
and protocol have received approval from necessary regu-
latory and ethics boards as well as an independent trial 
steering committee.
The trial will recruit 1200 patients, which began in June 
2013 and all patients will be followed up for a minimum 
of 12 months.
Trial participation may be terminated via voluntary 
refusal to continue at any time or through significant clin-
ical deterioration assessed by medical staff. Participants 
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suffering from trial-related problems or adverse events 
(AEs) may obtain medical treatment as compensation, 
and the trial is insured to compensate.
Patients
Patients are recruited from one tertiary centre (Leeds 
Teaching Hospitals Trust) and two district centres (Harro-
gate District Foundation Trust and Bradford District 
Trust). Participants will have an implantable pacemaker 
for bradycardia for at least 12 months according to any 
indication in current accepted clinical guidelines26 and 
be able to provide written informed consent. Both atrial 
and ventricular pacing burdens will be documented. 
Participants will be excluded if they have an implantable 
cardioverter defibrillator or cardiac resynchronisation 
device, are less than 18 years old, pregnant, awaiting heart 
transplantation or have a severe comorbidity with life 
expectancy of <1 year. We will also exclude people with 
significant cognitive impairment and any already under 
the care of HF services.
randomisation and interventions
Potential participants will receive a thorough explanation 
of the process of the trial, be notified of appointments via 
post and associated travel costs will be available to maxi-
mise compliance. Potential participants will be asked to 
voluntarily provide written informed consent prior to 
randomisation in line with the Declaration of Helsinki 
2002.
Consecutive pacemaker clinic attendees agreeing to 
participate will be enrolled and randomised centrally 
using a study-specific electronic system. Patients are 
randomised in a 1:1 ratio to (1) standard care pathway or 
(2) interventional pathway (figure 2). Usual care pathways 
follow National Institute for Health and Care Excellence 
(NICE) guidelines,27 and patients will undergo routine, 
usually annual, pacemaker follow-up. Interventional 
pathways consist of enhanced or optimised care predeter-
mined by each recruiting site. The echocardiographically 
informed pathways will consist of either a primary care 
driven management plan based on the echocardiogram 
that will be forwarded to the primary care team (enhanced 
care, n=300) if recruited in one of the district centres or 
a comprehensive care package consisting of optimised 
programming and medical therapy co-ordinated by a 
regional HF service (optimised care, n=300) if recruited 
in the tertiary centre. This interventional package will 
include the RV pacing avoidance algorithm (figure 1) 
and in those with LVSD (LVEF <50%) medical therapy 
following the NICE guidelines for the management of 
CHF.28 In the presence of LVSD, patients recruited at the 
tertiary centre will be referred to an outpatient HF clinic 
(optimised care), and in the district centres an echocar-
diogram report will be sent to the patients’ general prac-
titioner (enhanced care).
blinding
Practitioners and participants in this trial cannot be 
blinded to allocation of treatment due to the nature of 
the intervention. By not participating in baseline assess-
ments or medical and device optimisation and having no 
prior knowledge of participant allocation, the outcome 
assessor will remain blinded and thereby safe from 
detection bias.29 Unblinding of the assessors will only be 
permitted in certain circumstances, for example, when 
Figure 1 Ventricular pacing avoidance protocol.9
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the information is demanded to ensure appropriate 
management of the participants (eg, serious AEs).
outcome measures
The primary outcome measure is a combined endpoint 
of time from randomisation to date of first event of 
all-cause mortality or HF hospitalisation as assessed by 
the Endpoint Review Committee. The Endpoint Review 
Committee will ensure the quality of conduct and assess 
protocol deviations due to the low risk associated with 
intervention (echocardiography). They will monitor the 
safety of the trial and have unblinded access to efficacy 
data should it be required.
The main secondary outcome measure is the validation 
of a model to risk stratify people with a pacemaker for 
prevalent or future HF using simple clinical and pacing 
variables to predict the presence of LVSD at baseline and 
subsequently the combined outcome of HF hospitalisa-
tion and mortality at 1 year. Validation will be achieved by 
assessing against prespecified criteria, formed from the 
CIs of the initial pilot data analysis of the model.9
Other secondary outcome measures are to determine 
(1) the utility of BNP testing as a way to improve risk score 
for prevalent LVSD and future admissions, (2) hospital-
isation rates and mortality across randomised arms, (3) 
utility of a diagnosis of cardiac dysfunction on achieving 
standard of care medications and doses and (4) quality of 
life as measured by the EuroQol 5-Dimension (EQ-5D) at 
baseline and 12-month postenrollment.
All AEs related to the interventions will be recorded 
and monitored until resolved. Medical personnel will 
decide if continued trial participation is feasible based 
on these reports, with the final decision made by the 
participant.
Data collection
A clinical research co-ordinator (CRC) will collect infor-
mation on demographic characteristics such as gender, 
age, vital signs, height and weight and medication 
history. The patients’ medical history will be taken along 
with pacemaker data (implant date, implanted device, 
programmed pacemaker mode, BR and cumulative 
pacing percentages), and blood draw will be obtained. 
Biological specimens will be analysed and stored in the 
onsite research pathology laboratory. Patients randomised 
to intervention will undergo a baseline transthoracic 
echocardiogram, which will be assessed by the CRC. All 
data will be stored anonymously and will be locked once 
complete.
Figure 2 OPT-PACE study protocol.
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To ensure protocol adherence, a single research team 
will undertake all study-specific activity and be regularly 
monitored.
Digital follow-up will occur at 12-month postrecruit-
ment to record mortality and hospitalisation data and 
changes to medical therapy. Patient data regarding 
cardiac transplatation or device upgrade will be recorded 
and subsequently reported.
sample size
The trial is designed to detect a reduction in hospitalisa-
tion or mortality rate of 7.5% at 1 year in patients iden-
tified with cardiac dysfunction from 15% anticipated in 
patients randomised to the standard pathway.9 Given 
approximately one third of patients in both randomised 
arms are estimated to have cardiac dysfunction, a 7.5% 
reduction would be diluted to a 9% overall reduction 
in the enhanced pathway arm. To detect a reduction in 
events from 15% to 9% (equivalent to a HR equal to 0.58) 
using log-rank analysis with an overall type 1 error rate of 
0.05 (two-sided analysis) and a power of 0.90 requires a 
total of 146 events to be observed in at least 1070 partici-
pants (nQuery Advisor assuming 18-month recruitment) 
inflated to 1200 in anticipation of minimal drop-out.
statistical analysis plan
Primary analysis will be performed using the prespec-
ified endpoints in the intention-to-treat population (all 
randomised patients). Time to event will be summarised 
across randomised groups using Kaplan-Meier estimates, 
HRs and comparison across groups using log-rank tests, 
reporting 12-month survival.
Secondary analyses will estimate adjusted treatment 
effects through Cox proportional hazards regression 
model to describe the influence of baseline patient char-
acteristics on outcome. Factors to explore include age, 
gender, site, comorbidities, type of device, New York 
Heart Association (NYHA) class, medication, blood 
measures and underlying rhythm. A post hoc exploratory 
cost-effectiveness analysis will be conducted.
Quality of life data is collected at two time points and 
will be summarised graphically, conditional on patient 
survival. Quality-adjusted time to event analysis may 
be appropriate to report quality-adjusted estimates of 
12-month survival.
External validation of the risk model will be based on 
fitting the published model to the OPT-PACE trial data to 
report its goodness of fit. Data will be pooled, and strat-
ified by study, to remodel parameter estimates with the 
aim of improving precision.
Patient and public involvement
The research question developed as a large number of 
pacemaker patients was seen in HF clinic with deterio-
ration in their ventricular function and symptoms who 
were followed-up annually in pacemaker clinic and yet, 
these had not been detected. The study was initially 
discussed with a well-established local patient and public 
involvement (PPI) advisory group (AG) consisting 
of cardiovascular patients and their families. The AG 
particularly felt that undergoing all study assessments 
in 1 day was appealing to potential participants but that 
the intervention was not a large burden and that it was 
more important to know the effect on patient survival 
and the number of times patients were hospitalised, not 
just whether there was an improvement in heart function 
from optimised care in terms of outcome measures. Once 
the final protocol was established, it was reviewed by the 
PPI-AG along with patient information sheets to ensure 
the plain English was at an appropriate level. Regular 
updates will be presented regarding recruitment and 
any AEs. Study results will be discussed and an appro-
priate method of dissemination will be designed together 
between the AG and the researchers to deliver these to 
participants.
Ethics and dissemination
Amendments will be documented. Trial results will be 
communicated on a local level to healthcare profes-
sionals and patient involvement groups. Results will be 
published in international peer-reviewed journals with 
authorship as determined by the international committee 
of medical journal editors’ guidelines30 and highlighted 
using social media campaigns. The National Institute of 
Health Research will be made aware prior to publication 
but no publication restrictions apply.
Discussion
Patients with permanent pacemakers are at increased risk 
of prevalent HF with a reduced quality of life and inci-
dent HF leading to hospitalisations and a poorer prog-
nosis. Despite increasing recognition of this, and the 
development of device-based options to limit unnecessary 
ventricular pacing, patients with permanent pacemakers 
rarely undergo any assessment to identify prevalent HF 
or their future risk of HF. Pacemaker follow-up services 
have remained resolutely technical with intervals based 
on historical risk of pacemaker device failure rather than 
focusing on patient requirements in the face of negligible 
pacemaker failure rates and extended battery longevity.
A validated tool combining clinical and technical data 
by which patients’ risk of the one major complication of 
pacemaker therapy—HF—could be assessed, allowing indi-
vidualised follow-up intervals has the potential to substan-
tially improve patient experience while also offering the 
opportunity to focus screening and lead to the initiation 
of optimal therapy. Although there are several clinical 
and pacemaker-related features linked to the presence of 
cardiac dysfunction, no validated risk score exists to select 
those that should be referred for assessment.
The management pathways used in this trial will offer 
individualised healthcare and establish the relative bene-
fits of primary, secondary and tertiary expertise and 
interventions. Our previous data have shown that repro-
gramming to avoid RV pacing is safe and well tolerated 
by patients. Combining this with medical therapy for HF 
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in collaboration with a HF service as a new model of care 
for people with pacemakers is feasible and could improve 
their quality of life and overall prognosis while also being 
highly cost-effective. We aim to test the clinical effective-
ness of this approach when applied to a large number of 
patients at multiple sites.
ConClusIons
OPT-PACE is an important randomised controlled trial, 
supported by non-industry funding, that will investi-
gate whether assessing LV function to inform pacemaker 
programming and medical decisions can improve the 
morbidity and mortality in pacemaker patients compared 
with usual care.
The results will have implications for the stratification of 
pacemaker patients and the organisation of diagnostic and 
therapeutic pathways to reduce the incidence of HF in this 
population.
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